<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04593823</url>
  </required_header>
  <id_info>
    <org_study_id>scP-01-008</org_study_id>
    <nct_id>NCT04593823</nct_id>
  </id_info>
  <brief_title>Avoiding Treatment in the Hospital With Furoscix for the Management of Congestion in Heart Failure - A Pilot Study</brief_title>
  <acronym>AT HOME-HF</acronym>
  <official_title>A Multicenter, Randomized, Open Label, Controlled Study Evaluating the Effectiveness and Safety of Furoscix On-Body Infusor vs Continued Medical Therapy for Worsening Heart Failure</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>scPharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>scPharmaceuticals, Inc.</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multicenter, randomized, open label, controlled study evaluating the effectiveness,&#xD;
      and safety of the Furoscix Infusor vs continued medical therapy in patients with chronic&#xD;
      heart failure and fluid overload requiring augmentation in diuretic therapy outside of acute&#xD;
      care setting.&#xD;
&#xD;
      The study drug, Furoscix (furosemide injection 8 mg/ml), is a furosemide solution buffered to&#xD;
      a neutral pH containing 80 mg/10 mL for subcutaneous administration over 5 hours via the&#xD;
      Furoscix Infusor.&#xD;
&#xD;
      The study objectives are:&#xD;
&#xD;
        1. To provide pilot data on the effectiveness and safety to inform a pivotal trial.&#xD;
&#xD;
        2. To inform population enrichment strategies&#xD;
&#xD;
        3. To refine pivotal trial endpoints and analytical methods&#xD;
&#xD;
        4. To identify operational challenges of study design&#xD;
&#xD;
        5. To assess patient adherence, competence, and experience&#xD;
&#xD;
        6. To familiarize staff and patients with device application and use&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this study is to evaluate the effectiveness and safety of the Furoscix Infusor&#xD;
      vs continued medical therapy in patients with chronic heart failure and fluid overload&#xD;
      requiring augmentation in diuretic therapy outside of acute care setting. Up to 50 patients&#xD;
      will be randomly assigned (2:1) to receive Furoscix vs continued medical therapy.&#xD;
&#xD;
      The Treatment Phase comprises a pre-programmed bi-phasic 5-hour drug administration of&#xD;
      Furoscix (80 mg/10 mL) via the On-body Infusor. Subjects and/or their caregivers will be&#xD;
      trained on device preparation, placement and removal in accordance with product instructions&#xD;
      of use (IFU). Subjects should be transitioned back to their oral maintenance diuretic regimen&#xD;
      when clinically indicated at the discretion of the investigator.&#xD;
&#xD;
      Over the initial 7 days, all subjects will receive daily clinic or phone follow-up by the&#xD;
      study staff. Decision of treatment with Furoscix in the intervention arm as well as changes&#xD;
      in oral diuretic dosing in the control arm will be determined by the treating physician in&#xD;
      coordination with the study nurse. Safety labs will be done on Days 1, 3, 7 and 30.&#xD;
&#xD;
      After Subjects have been transitioned to their oral maintenance diuretic regimen, additional&#xD;
      doses of Furoscix (for Furoscix group) or IV diuretics (for Treat as Usual group) can be&#xD;
      prescribed during the 30-day study period as needed based on the presence of congestion&#xD;
      symptoms (e.g. dyspnea, edema, and/or excess weight gain) as determined by the investigator.&#xD;
&#xD;
      The Follow-Up Phase will include a visit to the clinic on Day 30 +/- 5 days where&#xD;
      effectiveness and safety assessments will be performed including limited physical exam&#xD;
      (including NYHA Class), Composite Congestion Score (CCS), 5-point Current Dyspnea Score,&#xD;
      7-point Dyspnea Score, vital signs, laboratory analyses, KCCQ-12, Visual Analog Score (VAS),&#xD;
      6MWT and adverse events.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 3, 2021</start_date>
  <completion_date type="Anticipated">April 2022</completion_date>
  <primary_completion_date type="Anticipated">March 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Compare the Cardiovascular death hierarchically using Finkelstein-Schoenfeld Method.</measure>
    <time_frame>30 Days</time_frame>
    <description>Cardiovascular deaths will be compared to all other patients at 30 days</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Compare the Heart Failure hospitalization hierarchically using Finkelstein-Schoenfeld Method.</measure>
    <time_frame>30 Days</time_frame>
    <description>Heart Failure hospitalizations will be compared to all other patients at 30 days</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Compare the Urgent ED/Clinic visits for worsening heart failure hierarchically using Finkelstein-Schoenfeld Method.</measure>
    <time_frame>30 Days</time_frame>
    <description>Urgent ED/Clinic visits will be compared to all other patients at 30 days</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Compare NT-proBNP for worsening heart failure hierarchically using Finkelstein-Schoenfeld Method.</measure>
    <time_frame>30 Days</time_frame>
    <description>NT-proBNP will be compared to all other patients at 30 days</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Days alive and heart failure event-free days</measure>
    <time_frame>30 Days</time_frame>
    <description>Hospitalization for heart failure or ED visits for heart failure over 30 days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in patient global assessment via visual analog scale (VAS)</measure>
    <time_frame>30 Days</time_frame>
    <description>Change from baseline in patient global assessment via visual analog scale (VAS) across follow-up timepoints</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in composite congestion score (CCS)</measure>
    <time_frame>30 Days</time_frame>
    <description>Change from baseline in composite congestion score (CCS) across follow-up timepoints</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in 5-point Current Dyspnea Score</measure>
    <time_frame>30 Days</time_frame>
    <description>Change from baseline in 5-point Current Dyspnea Score across follow-up timepoints</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>7-point Dyspnea Score across follow-up time points</measure>
    <time_frame>30 Days</time_frame>
    <description>Change from baseline in 7-point Dyspnea Score across follow-up time points</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health-related quality of life across follow-up time points</measure>
    <time_frame>30 Days</time_frame>
    <description>Change from baseline in health-related quality of life across follow-up timepoints</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum creatinine across follow-up time points</measure>
    <time_frame>30 Days</time_frame>
    <description>Change from baseline in serum creatinine across follow-up timepoints</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ambulatory body weight across follow-up time points</measure>
    <time_frame>30 Days</time_frame>
    <description>Change from baseline in ambulatory body weight across follow-up timepoints</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Six-Minute Walk Test (6MWT) across follow-up time points</measure>
    <time_frame>30 Days</time_frame>
    <description>Change from baseline in Six-Minute Walk Test (6MWT) across follow-up timepoints</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Heart Failure</condition>
  <arm_group>
    <arm_group_label>Furoscix Infusor</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Furoscix (furosemide injection, 8 mg/mL) administered subcutaneously over 5 hours via the Furoscix Infusor. The Infusor is applied to the abdomen via a medical grade adhesive and delivers a subcutaneous infusion of Furoscix through a pre-programmed, biphasic delivery profile with 30 mg (3.75 mL) administered over the first hour, followed by 12.5 mg (1.56 mL) per hour for the subsequent 4 hours (Total dose is 80 mg (10 mL) over 5 hours).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Continued Medical Therapy</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>The subjects enrolled in this arm will receive treatment as usual</description>
  </arm_group>
  <intervention>
    <intervention_type>Combination Product</intervention_type>
    <intervention_name>Furoscix Infusor</intervention_name>
    <description>Furoscix Infusor, a drug-device combination product for subcutaneous delivery of Furoscix, buffered furosemide injection, 8 mg/mL (total dose = 80 mg dose) administered subcutaneously for 5 hours.</description>
    <arm_group_label>Furoscix Infusor</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Subjects are eligible for inclusion only if all the following criteria are met:&#xD;
&#xD;
          1. Age 18-80 years.&#xD;
&#xD;
          2. Diagnosis of symptomatic chronic heart failure (NYHA Class II-IV) with background loop&#xD;
             diuretic therapy for at least 4 weeks.&#xD;
&#xD;
          3. Need for augmented diuresis outside of the acute care setting as determined by the&#xD;
             investigator.&#xD;
&#xD;
          4. On background therapy including daily total furosemide equivalent dose (40-160 mg) of&#xD;
             loop diuretic or equivalent.&#xD;
&#xD;
          5. The subject must have signs of volume expansion, defined as two or more of the&#xD;
             following six signs:&#xD;
&#xD;
               1. jugular venous distention&#xD;
&#xD;
               2. edema (≥ 1+)&#xD;
&#xD;
               3. ascites&#xD;
&#xD;
               4. pulmonary congestion on chest x-ray&#xD;
&#xD;
               5. pulmonary rales&#xD;
&#xD;
               6. NT-proBNP ≥1000 pg/ml (1400 for patients in atrial fibrillation) or, for patients&#xD;
                  not on Entresto, BNP ≥200 (400 for patients in atrial fibrillation)&#xD;
&#xD;
          6. Increase over the preceding 30 days in at least one of the following symptoms&#xD;
             characteristic of worsening heart failure:&#xD;
&#xD;
               1. dyspnea&#xD;
&#xD;
               2. fatigue&#xD;
&#xD;
               3. exercise intolerance&#xD;
&#xD;
          7. Adequate environment for at home administration of Furoscix by patient or caregiver.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        A Subject is not eligible for inclusion if any of the following criteria apply:&#xD;
&#xD;
          1. Suspected high risk clinical instability with outpatient treatment.&#xD;
&#xD;
          2. Presence of a complicating condition, other than heart failure likely to require&#xD;
             hospitalization in next 30 days.&#xD;
&#xD;
          3. Pregnant women or women of childbearing age who are not willing to use an adequate&#xD;
             form of contraception.&#xD;
&#xD;
          4. Known allergy to the active and inactive ingredients of the study medication or device&#xD;
             adhesive.&#xD;
&#xD;
          5. On experimental medication or currently participating in another interventional&#xD;
             research study.&#xD;
&#xD;
          6. eGFR &lt; 20&#xD;
&#xD;
          7. Serum potassium at baseline &gt; 5.4 or &lt; 3.6&#xD;
&#xD;
          8. Concomitant infection&#xD;
&#xD;
          9. Heart rate &gt; 110&#xD;
&#xD;
         10. Received IV furosemide or bumetanide within last 24 hours&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marvin A Konstam, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Principal Investigator</affiliation>
  </overall_official>
  <overall_official>
    <last_name>James E Udelson, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Principal Investigator</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Barbara Cornelius</last_name>
    <phone>6172066810</phone>
    <email>bcornelius@scpharma.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>John Mohr, PharmD</last_name>
    <email>jmohr@scpharma.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Heart Group of Eastern Shore</name>
      <address>
        <city>Fairhope</city>
        <state>Alabama</state>
        <zip>36532</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Pursley, MD</last_name>
    </contact>
    <investigator>
      <last_name>Michael Pursley, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Heart Center Research, LLC</name>
      <address>
        <city>Huntsville</city>
        <state>Alabama</state>
        <zip>35801</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Herbert Haught, MD</last_name>
    </contact>
    <investigator>
      <last_name>Herbert Haught, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hartford Hospital</name>
      <address>
        <city>Hartford</city>
        <state>Connecticut</state>
        <zip>06102</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joseph Radojevic, MD</last_name>
    </contact>
    <investigator>
      <last_name>Joseph Radojevic, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Aventura Clinical Research, LLC</name>
      <address>
        <city>Aventura</city>
        <state>Florida</state>
        <zip>33541</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Leonard Pianko, MD</last_name>
    </contact>
    <investigator>
      <last_name>Leonard Pianko, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Florida</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32611</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mustafa Ahmed, MD</last_name>
    </contact>
    <investigator>
      <last_name>Mustafa Ahmed, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Elite Cardiac Research</name>
      <address>
        <city>Hialeah</city>
        <state>Florida</state>
        <zip>33012</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Manuel Bouza, MD</last_name>
    </contact>
    <investigator>
      <last_name>Manuel Bouza, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>First Coast Cardiovascular Institute</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32256</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sumant Lamba, MD</last_name>
    </contact>
    <investigator>
      <last_name>Sumant Lamba, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cardiology Consultants</name>
      <address>
        <city>Pensacola</city>
        <state>Florida</state>
        <zip>32501</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pelbreton Balfour, MD</last_name>
    </contact>
    <investigator>
      <last_name>Pelbreton Balfour, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>James A. Haley Veerans Hospital</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fabio Leonelli, MD</last_name>
    </contact>
    <investigator>
      <last_name>Fabio Leonelli, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital - Augusta</name>
      <address>
        <city>Augusta</city>
        <state>Georgia</state>
        <zip>30901</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Arthur B Chandler, MD</last_name>
    </contact>
    <investigator>
      <last_name>Arthur B Chandler, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Advocate Health and Hospitals</name>
      <address>
        <city>Downers Grove</city>
        <state>Illinois</state>
        <zip>60515</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ali Valika, MD</last_name>
    </contact>
    <investigator>
      <last_name>Ali Valika, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UnityPoint Health - Methodist Hospital</name>
      <address>
        <city>Peoria</city>
        <state>Illinois</state>
        <zip>61606</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alexander Adler, MD</last_name>
    </contact>
    <investigator>
      <last_name>Alexander Adler, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Michigan Heart</name>
      <address>
        <city>Ypsilanti</city>
        <state>Michigan</state>
        <zip>48197</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ahmad Mizyed, MD</last_name>
    </contact>
    <investigator>
      <last_name>Ahmad Mizyed, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St. Louis Heart and Vascular</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63136</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gil Vardi, MD</last_name>
    </contact>
    <investigator>
      <last_name>Gil Vardi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Icahn School of Medicine at Mount Sinai</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Johanna Contreras</last_name>
    </contact>
    <investigator>
      <last_name>Johanna Contreras, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cone Health Medical Group</name>
      <address>
        <city>Greensboro</city>
        <state>North Carolina</state>
        <zip>27455</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dalton McLean, MD</last_name>
    </contact>
    <investigator>
      <last_name>Dalton McLean, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Lancaster General Hospital</name>
      <address>
        <city>Lancaster</city>
        <state>Pennsylvania</state>
        <zip>17602</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Robert Donovan, MD</last_name>
    </contact>
    <investigator>
      <last_name>Robert Donovan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Wisconsin</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53792</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aurangzeb Baber, MD</last_name>
    </contact>
    <investigator>
      <last_name>Aurangzeb Baber, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>October 2, 2020</study_first_submitted>
  <study_first_submitted_qc>October 13, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 20, 2020</study_first_posted>
  <last_update_submitted>November 8, 2021</last_update_submitted>
  <last_update_submitted_qc>November 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

